BioCentury
ARTICLE | Company News

Vertex gets reimbursement deal for Orkambi in Sweden

June 22, 2018 5:57 PM UTC

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said June 18 it agreed to a long-term access agreement for cystic fibrosis drug Orkambi lumacaftor/ivacaftor with Swedish authorities. Beginning July 1, Orkambi will be reimbursed in Sweden at an undisclosed price to treat CF patients ages six and older who have two copies of the delta F508 mutation -- its approved indication in the EU.

Vertex said the agreement includes "a framework for the assessment and access" to future CF medicines. The company declined to disclose details...

BCIQ Company Profiles

Vertex Pharmaceuticals Inc.